Canada markets closed

TFF Pharmaceuticals, Inc. (0K3.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
5.300.00 (0.00%)
At close: 09:16AM CEST
Full screen
Previous Close5.30
Open5.30
Bid5.50 x N/A
Ask5.65 x N/A
Day's Range5.15 - 5.15
52 Week Range3.76 - 9.75
Volume1,007
Avg. Volume23
Market Cap137.483M
Beta (5Y Monthly)2.14
PE Ratio (TTM)N/A
EPS (TTM)-1.17
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
  • GlobeNewswire

    TFF Pharmaceuticals to Participate at the H.C. Wainwright Global Investment Conference

    FORT WORTH, Texas, May 20, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be virtually participating in the H.C. Wainwright Global Investment Conference being held May 23 - 26, 2022. Company management will also be participating in virtual one-o

  • Zacks

    TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Misses Revenue Estimates

    TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of 13.16% and 33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

    Announced Collaboration with Catalent to Further Expand Thin Film Freezing Applications with a Focus on Biologic Drug Development Announced Second CRADA Agreement with USAMRIID and Geneva Foundation to Develop Novel Therapies Using Thin Film Freezing to Combat SARS-CoV-2, Ebola, and Marburg Viruses Initiated Phase 2 Trials of Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder With Interim Data for Each Program Expected Later in 2022 Significant Progress Made in Inhaled Niclosamide Powder